Your browser doesn't support javascript.
loading
In vitro digestion of starches in a dynamic gastrointestinal model: an innovative study to optimize dietary management of patients with hepatic glycogen storage diseases.
Nalin, Tatiéle; Venema, Koen; Weinstein, David A; de Souza, Carolina F M; Perry, Ingrid D S; van Wandelen, Mario T R; van Rijn, Margreet; Smit, G Peter A; Schwartz, Ida V D; Derks, Terry G J.
Afiliação
  • Nalin T; Post-Graduation Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
J Inherit Metab Dis ; 38(3): 529-36, 2015 May.
Article em En | MEDLINE | ID: mdl-25224825
Uncooked cornstarch (UCCS) is a widely used treatment strategy for patients with hepatic glycogen storage disease (GSD). It has been observed that GSD-patients display different metabolic responses to different cornstarches. The objective was to characterize starch fractions and analyze the digestion of different starches in a dynamic gastrointestinal in vitro model. The following brands of UCCS were studied: Argo and Great Value from the United States of America; Brazilian Maizena Duryea and Yoki from Brazil; Dutch Maizena Duryea from the Netherlands. Glycosade, a modified starch, and sweet polvilho, a Brazilian starch extracted from cassava, were also studied. The starch fractions were analyzed by glycemic TNO index method and digestion analyses were determined by the TIM-1 system, a dynamic, computer-controlled, in vitro gastrointestinal model, which simulates the stomach and small intestine. The final digested amounts were between 84 and 86% for the UCCS and Glycosade, but was 75.5% for sweet povilho. At 180 min of the experiment, an important time-point for GSD patients, the digested amount of the starches corresponded to 67.9-71.5 for the UCCS and Glycosade, while it was 55.5% for sweet povilho. In an experiment with a mixture of sweet polvilho and Brazilian Maizena Duryea, a final digested amount of 78.4% was found, while the value at 180 min was 61.7%. Sweet polvilho seems to have a slower and extended release of glucose and looks like an interesting product to be further studied as it might lead to extended normoglycemia in GSD-patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amido / Doença de Depósito de Glicogênio Tipo I / Digestão / Glucose Limite: Humans Idioma: En Revista: J Inherit Metab Dis Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amido / Doença de Depósito de Glicogênio Tipo I / Digestão / Glucose Limite: Humans Idioma: En Revista: J Inherit Metab Dis Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Brasil